Studies reporting BPC-157's mechanism, musculoskeletal outcomes, metabolism, and safety were included
One patch is intended per day
Last Published 06.01.2026 Effective Date: 06.01.2026 This policy addresses the use of Leqvio (inclisiran) for the treatment of primary hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), and clinical atherosclerotic cardiovascular disease (ASCVD)
Monitor for: Gastrointestinal symptoms: Nausea or vomiting (occurring in approximately 1520% of patients at therapeutic doses per FDA labeling) Abdominal pain or cramping Diarrhea or constipation Loss of appetite or early satiety Bloating or abdominal distension Hypoglycemia indicators (particularly if you take other diabetes medications): Trembling, shakiness, or sweating Rapid heartbeat or palpitations Dizziness, lightheadedness, or confusion Hunger or irritability Headache or blurred vision Injection site reactions: Bruising, swelling, or hematoma formation Persistent pain or tenderness Redness or warmth suggesting inflammation Hardness or nodule formation under the skin Semaglutide's mechanism involves glucose-dependent insulin secretion, meaning hypoglycemia risk is generally low when used as monotherapy
